Sample conc. (µg/mL) Compound No.	Growth inhibition %						IC₅₀ (µM/L)
Sample conc. (µg/mL) Compound No.	50	25	12.5	6.25	3.13	1.6	IC₅₀ (µM/L)
2	81.73	65.02	39.08	21.46	10.59	3.20	59.73
3	64.81	56.58	43.37	34.70	23.03	11.54	71.76
4	73.61	57.42	40.81	33.50	24.62	15.84	78.86
5	57.48	48.74	35.82	27.14	20.38	15.55	>100
6	87.08	66.57	41.14	25.41	9.19	1.38	59.93
7	85.04	72.69	50.38	28.67	9.75	1.27	41.33
8	83.71	61.58	33.25	12.68	4.22	0.00	70.82
9	83.46	52.65	33.96	17.07	8.26	2.11	78.38
10	90.38	87.53	77.16	47.12	31.39	12.58	16.35
11	75.41	53.45	42.52	30.35	16.69	8.86	46.27
12	71.28	58.09	26.91	18.02	11.68	4.86	42.25
13	72.66	39.07	18.28	9.13	1.84	0.00	72.91
14	74.81	37.46	17.07	6.94	3.12	0.00	76.78
15	88.97	77.44	61.57	45.44	26.13	14.39	20.99
16	84.36	50.68	21.46	8.30	2.17	0.00	76.01
17	83.76	73.57	39.05	30.43	20.19	13.94	34.96
18	83.65	70.57	59.45	27.08	10.52	4.84	31.85
19	92.11	86.69	77.52	38.72	20.64	10.36	18.79
20	84.07	73.89	53.36	29.14	16.87	7.53	27.04
21	85.88	74.64	48.76	31.68	16.04	7.46	31.34
22	80.15	66.32	28.25	16.48	5.81	2.42	39.84
23	91.03	83.09	74.41	60.58	48.53	25.08	7.09
24	92.14	86.26	78.62	63.85	40.19	23.47	10.58
25	73.37	46.82	30.46	16.22	5.85	1.27	86.15
26	67.52	55.94	26.38	20.59	13.84	6.39	72.81
27	72.18	38.42	14.26	3.52	1.04	0.00	>100
28	70.26	31.38	20.41	12.84	4.78	1.06	96.61
29	91.26	80.92	66.71	43.36	21.89	10.33	19.95
Doxorubicin	89.05	85.71	83.10	78.97	69.68	51.75	8.55